Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
R-3750 · 1 trial · 1 indication
Number of participants experiencing one or more treatment-emergent adverse events following administration of R-3750 or placebo.
| Arm | Type | Description |
|---|---|---|
| Arm 1: R-3750, 9E10 CFU/day orally once daily for 12 weeks | EXPERIMENTAL | Participants randomized to the experimental arm will receive R-3750 at a dose of 9E10 colony-forming units (CFU) per day, administered orally once daily from Day 1 through Day 84 (12 weeks). |
| Arm 2: Matching placebo orally once daily for 12 weeks | PLACEBO_COMPARATOR | Participants randomized to the placebo comparator arm will receive matching placebo administered orally once daily from Day 1 through Day 84 (12 weeks). |
| Name | Type | Description |
|---|---|---|
| R-3750 | DRUG | R-3750 DP is a live biotherapeutic product consisting of Lactococcus lactis engineered to express Surface Layer Protein A (SlpA), formulated in enteric-coated capsules for oral administration. Participants randomized to R-3750 will receive 9E10 colony-forming units (CFU) per day orally once daily from Day 1 through Day 84. |
| Placebo | DRUG | Matching placebo will be administered orally once daily from Day 1 through Day 84. |
Inclusion Criteria: * Age 18 to 80 years, inclusive, at the time of informed consent. * Able and willing to provide written informed consent and comply with study procedures and study visits. * Documented diagnosis of Crohn's disease with symptoms/onset of disease at least 3 months prior to Screeni...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 6 | PHASE3 | Duvakitug |
| Eli Lilly and Company | LLY | 8 | PHASE3 | Mirikizumab |
| AbbVie, Inc. | ABBV | 14 | PHASE3 | Risankizumab, Risankizumab On-Body Injector |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 16 | PHASE3 | Vedolizumab |
| Johnson & Johnson | JNJ | 13 | PHASE3 | Ustekinumab |
| Merck & Co., Inc. | MRK | 2 | PHASE3 | Tulisokibart |
| AstraZeneca PLC | AZN | 2 | PHASE2 | AZD7798 |
| Abivax SA Sponsored ADR | ABVX | 1 | PHASE2 | Obefazimod |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Spyre Therapeutics, Inc | SYRE | 1 | PHASE2 | SPY001, SPY002, SPY003 |
| Palisade Bio, Inc. | PALI | 1 | PHASE1 | PALI-2108 |
| Novartis AG Sponsored ADR | NVS | 1 | - | Undisclosed |
| Amgen Inc. | AMGN | 1 | N/A | Undisclosed |
| TScan Therapeutics, Inc. | TCRX | 1 | - | Undisclosed |